US EditionLilly Finds Impurity in Compounded Version of Its Weight-Loss Drug ...
Eli Lilly found a significant impurity in compounded tirzepatide-vitamin B12 products in all tested samples and urged a nationwide recall to prevent potential health risks.
- On Thursday, Eli Lilly issued a public warning about compounded tirzepatide products mixed with vitamin B12, urging the FDA to initiate a nationwide recall due to identified safety risks.
- Lilly's testing of compounding pharmacies and telehealth networks found "significant levels of an impurity that results from a chemical reaction between tirzepatide and B12," with effects in humans unknown.
- The impurity appeared in all ten samples tested by the company. Chief Medical Officer David Hyman warned that adding B12 "without clinical testing or FDA review introduces additional unknown risks."
- Lilly stated that manufacturers are mixing tirzepatide with glycine and carnitine, calling these "personalizers" a way to circumvent the law and create untested combination drugs.
- The FDA previously issued warning letters to 30 telehealth companies for misleading claims, and as shortages have ended, the agency is taking "decisive steps" against copycat products.
14 Articles
14 Articles
Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks
WASHINGTON — Compounded weight-loss drugs that contain vitamin B12 and the main ingredient in Eli Lilly’s Zepbound could present health risks to consumers due to a previously unidentified impurity caused in the preparation, the U.S. drugmaker said in a public letter released on Thursday.
Impurity in Some Compounded Tirzepatide 'Potentially Dangerous,' Eli Lilly Warns
(MedPage Today) -- Compounded versions of tirzepatide (Mounjaro, Zepbound) containing vitamin B12 pose a potential safety risk to the public, Eli Lilly warned in an open letter on Thursday. Following laboratory testing, the drugmaker said it uncovered...
Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12 - Eli Lilly (NYSE:LLY)
Eli Lilly warns that an impurity formed in compounded tirzepatide mixed with vitamin B12 could pose unknown health risks. Importance Rank: 1
Eli Lilly Warns of Safety Risk From Compounded Zepbound Drugs Mixed With Vitamin B12
Pharmaceutical giant Eli Lilly is warning patients about the potential danger of taking compounded tirzepatide, marketed as Zebound and Mounjaro, mixed with vitamin B12. After testing copycat drug products containing the tizepatide and B12 combination, the drug manufacturer found “significant levels of impurity” resulting from a chemical reaction between the two substances. “Lilly has repeatedly expressed grave concerns about the safety of mass-…
Hidden Dangers: Eli Lilly Sounds Alarm Over Compounded Weight-Loss Drugs
Eli Lilly alerts consumers to potential health risks in compounded weight-loss drugs combining vitamin B12 and tirzepatide, citing impurities. The company has sued compounders marketing unauthorized copies of its diabetic medications. FDA warns compounded products lack safety reviews, and Lilly urges a national recall.
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
